Inspira Announces 97.3% Accuracy Results for HYLA™ Blood Sensor, Advancing Toward FDA Submission for Clearance

Core Insights - Inspira Technologies announced pivotal results for its HYLA blood sensor, achieving 97.35% accuracy in performance testing, which supports its upcoming FDA submission [1][2][6] - The HYLA sensor is designed for continuous, real-time monitoring of key blood parameters, addressing urgent needs in operating rooms and critical care [3][6] - The company is positioned to penetrate the broader disposables market with a planned razor-and-blade recurring revenue model [2][6] Company Overview - Inspira Technologies specializes in advanced respiratory support and real-time blood monitoring solutions, with FDA-cleared products including the INSPIRA ART100 system [4] - The company is advancing the HYLA platform, which offers continuous, non-invasive monitoring and is compatible with various medical procedures [4][6] - Recent internal shifts within the company may align with broader industry trends such as consolidation and potential strategic partnerships [4]